IDYA News and Press, IDEAYA Biosciences Inc. From 12/01/25

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at ap...

2025-11-25 16:58:07 ET Investment Overview Ideaya Biosciences, Inc. ( IDYA ) is a "precision medicine oncology" company that IPO'd in May 2019, raising $57.5m via the issuance of 5.75m shares at $10 per share. Stock is valued at $35 per share at the time of writing, ...

2025-11-24 10:28:08 ET Shares of IDEAYA Biosciences, Inc. (NASDAQ: IDYA) traded at a new 52-week high today and are currently trading at $35.03. So far today, approximately 116.03k shares have been exchanged, as compared to an average 30-day volume of 959.75k shares. IDEAYA Bioscien...

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...

Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transformin...

2025-11-06 19:06:10 ET IDEAYA Biosciences, Inc. (IDYA) Citi's 2025 SMID Cap Biopharma Call Series November 6, 2025 12:00 PM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call ...

2025-11-04 06:24:04 ET More on IDEAYA Biosciences IDEAYA Biosciences, Inc. (IDYA) Presents at 22nd International Congress - Slideshow IDEAYA Biosciences, Inc. (IDYA) Presents at ESMO Congress 2025 - Slideshow IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&...

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to ...

Hess Midstream LP Class A Representing Limited Partner Interests (HESM) is expected to report $0.73 for Q3 2025 IDEAYA Biosciences Inc. (IDYA) is expected to report $0 for Q3 2025 Unum Group (UNM) is expected to report $2.15 for Q3 2025 CNA Financial Corporation (CNA) is expected to r...

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...